Aspira Women's Health Inc. Reports Board and Compensation Changes

Ticker: AWHL · Form: 8-K · Filed: 2024-12-16T00:00:00.000Z

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

Related Tickers: AWHI

TL;DR

Aspira Women's Health Inc. (AWHI) filed an 8-K detailing board changes and executive comp updates as of Dec 16, 2024.

AI Summary

Aspira Women's Health Inc. announced on December 16, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain directors and the election of new ones, alongside updates to compensatory plans for key officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may affect future business operations and financial performance.

Key Players & Entities

FAQ

What specific items are covered in the Form 8-K filed by Aspira Women's Health Inc. on December 16, 2024?

The Form 8-K covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.

Who is the filer of this Form 8-K?

The filer is Aspira Women's Health Inc.

On what date was this Form 8-K reported?

The earliest event reported was on December 16, 2024.

In which state was Aspira Women's Health Inc. incorporated?

Aspira Women's Health Inc. was incorporated in Delaware.

What is the SEC file number for Aspira Women's Health Inc.'s filing?

The SEC file number is 001-34810.

From the Filing

0001493152-24-050269.txt : 20241216 0001493152-24-050269.hdr.sgml : 20241216 20241216171339 ACCESSION NUMBER: 0001493152-24-050269 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241216 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241216 DATE AS OF CHANGE: 20241216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241552766 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2024-12-16 2024-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024       Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12117 Bee Caves Road Building III Suite 100     Austin, Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Elec

View on Read The Filing